Ondine Biomedical Inc. has made significant commercial progress to date in 2024, ahead of management's expectations. Ondine's Steriwave®? technology is deploying in eight new healthcare facilities, including six new hospitals.

This brings the total number of hospitals to 22, representing a 38% increase year-to-date and nearly quadruple the number a year ago. Two orthopedic surgeon group practices in the Toronto area will also shortly begin offering Steriwave to patients undergoing elective orthopedic procedures. In addition, The Ottawa Hospital (TOH) has confirmed it is significantly expanding its use of Steriwave, building upon the success of its pilot and a comprehensive cost-benefit assessment within spine surgeries.

This expansion means that Steriwave will now be used across an additional site, and also extends its application from spinal surgeries to also include TOH's orthopedic and vascular surgery patients. Annually, Steriwave will now be used prior to approximately 2,600 surgical procedures at TOH, a threefold increase from the Steriwave pilot. Discussions are ongoing with medical device distributors to further expand the commercial reach of Steriwave.

The new commercial deployments of Steriwave described beyond the TOH expansion are paid adoptions that have begun or were agreed before the end of February 2024: The first three hospitals in Spain, including the Hospital Universitario La Paz (HULP) in Madrid for a paid pilot of patients undergoing elective orthopedic procedures. As anticipated by a previous announcement, these are the first sign-ups through its distribution partner in Spain; Sturgeon Community Hospital, Alberta, (Alberta Health Services (AHS), Canada's largest integrated health system). Sturgeon Community Hospital is the third AHS hospital to deploy Steriwave.

Steriwave has been deployed for the reduction of surgical site infections (SSIs) for patients undergoing breast reconstruction surgeries and elective orthopedic procedures; Nanaimo Regional General Hospital, British Columbia, (Island Health Authority) has deployed Steriwave to reduce HAIs in patients undergoing hip and knee surgeries; Two orthopedic surgeon group practices in the Toronto area will also begin offering Steriwave on a patient-pay basis to patients undergoing elective orthopedic procedures. These groups operate from Toronto Western Hospital, St Mary's General Hospital, and Grand River Hospital all of which are in the Greater Toronto region in Ontario, Canada.